Inspire Medical Systems (INSP) Shares Decline—Here’s What Caused It

Recent Developments

Shares of Inspire Medical Systems (NYSE:INSP), a company specializing in medical technology, dropped by 7.5% during afternoon trading after a significant inflation report was released. The data showed that prices paid by U.S. producers increased more than expected in January.

The Producer Price Index (PPI), which tracks inflation at the wholesale level before it impacts consumers, rose by 0.5% last month. This exceeded economists’ predictions of a 0.3% increase. The higher-than-anticipated inflation figures have heightened investor concerns, suggesting that the Federal Reserve may postpone any interest rate reductions that many had been hoping for. Prolonged periods of elevated interest rates can put pressure on company valuations and increase borrowing costs, resulting in a broader market decline that affects sectors such as healthcare and medical devices.

Market reactions to news can sometimes be exaggerated, and sharp declines in share prices may create attractive entry points for investors seeking quality stocks. Considering this, is now a good moment to consider buying Inspire Medical Systems?

Market Insights

Inspire Medical Systems’s stock is known for its high volatility, with 31 instances of price swings greater than 5% over the past year. Today’s decline signals that investors view the latest inflation data as significant, but not enough to fundamentally alter their outlook on the company.

The last major price movement occurred about 23 hours ago, when the stock surged 19.7% following reports that the Centers for Medicare & Medicaid Services (CMS) plans to assign dedicated C-codes for the Inspire V device in the April 2026 Integrated Outpatient Code Editor (IOCE) update. Analysts at KeyBanc highlighted that this decision resolves recent uncertainties around reimbursement, which had previously weighed on the stock. The introduction of specific C-codes will streamline billing for hospitals and surgical centers, making payments for Inspire’s neurostimulation therapy for obstructive sleep apnea more predictable and potentially higher. This regulatory update has helped restore investor confidence after a period of instability. Earlier in 2026, Inspire Medical Systems had reduced its revenue outlook due to challenges related to coding. The new C-codes are seen as a positive regulatory development that removes these obstacles and could accelerate adoption of the company’s technology.

Since the start of the year, Inspire Medical Systems shares have fallen 31.1%. Currently trading at $63.60 per share, the stock is down 65.7% from its 52-week high of $185.59 reached in February 2025. An investor who purchased $1,000 worth of shares five years ago would now have an investment valued at $255.18.

While many investors are focused on Nvidia’s record highs, a lesser-known semiconductor company is quietly leading in a crucial AI component that industry giants rely on.